Custom Overcoming the challenges of NGS-based RNA profiling using limited, precious samples

Date: This event took place on May 10, 2016

Custom webcast sponsor retains sole responsibility for content.

Watch on-demand

Performing gene expression profiling with next generation sequencing (NGS) on a variety of sample types (formalin-fixed, paraffin-embedded (FFPE) tissues, plasma, serum, PAXgene, cells and tissues) can be challenging for researchers.

For example, generating high-quality expression data from the RNA extracted from FFPE samples can be difficult due to limited yields and crosslinking-induced fragmentation of nucleic acids. This can make downstream analysis problematic, especially when scaling-up into routine profiling. Conversely, when using plasma or serum, a large amount of sample is required to produce enough isolated RNA for traditional molecular profiling.

In this webcast, we discuss how the HTG EdgeSeq system can be used to overcome the challenges of expression profiling of limited, precious samples. This extraction-free method can be used to quantify mRNA or miRNA from very small, clinically relevant FFPE tissues, serum/plasma, PAX gene, and cell samples.  Furthermore, researchers will gain knowledge on how to leverage the power of NGS paired with the specificity of the HTG EdgeSeq chemistry for expression profiling of up to 2,560 mRNAs from a single FFPE slide using lysis only sample preparation.

Watch on-demand

Speakers

  • BJ Kerns, HTG Molecular Diagnostics

    BJ Kerns, HTG Molecular Diagnostics

    BJ Kerns brings more than 30 years of technical, marketing and business development experience along with a successful track record in diagnostics. Prior to joining HTG, Kerns was the Director of Integrated Solutions and Molecular Diagnostics at Promega Corp. Inc.

    A seasoned diagnostics executive, Kerns held several positions at Ventana Medical Systems Inc., including Director of Women’s Health, Director of Strategic Marketing and Sr. Director of Product Technical Support in Operations. While at Ventana she launched the first FDA-cleared companion diagnostic PATHWAY® HER-2. Kerns has also managed a variety of functions at BioGenex and Becton Dickinson, including business development, sales and marketing, and research and development.

    As a board certified Medical Technologist, she held several positions at Duke University Medical Center both in Pathology and the Comprehensive Cancer Center. Kerns received an AAS in Medical Technology from Elon College in Elon, North Carolina, and a BS in Health Care Management from Century University in Albuquerque, New Mexico. She has received a certification in Managing Strategic Resources from Darden Executive Education at the University of Virginia.

    She has published 60+ scientific papers and has presented over a 100 workshops and posters in her career.

  • Dr. Jayshan Carpen, Springer Nature

    Moderator: Dr. Jayshan Carpen, Springer Nature

    Jayshan is a Senior Publishing Manager for Springer Nature and oversees the custom multimedia unit. Previously he ran science events at the Royal Institution of Great Britain. He received his PhD from the University of Surrey, UK in Neurogenetics. His doctoral thesis focused on identifying polymorphisms associated with diurnal preference and circadian sleep disorders.